Loading... Please wait.
Company profile
TiGenix NV is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells. The lead product, Cx601, has successfully completed a European Phase III clinical trial for the treatment of complex perianal fistulas - a severe, debilitating complication of Crohn's disease. Cx601 has been filed for regulatory approval in Europe and a global Phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017. TiGenix NV has entered into a licensing agreement with Takeda, a global pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to develop and commercialize Cx601 for complex perianal fistulas outside the U.S. The second adipose-derived product, Cx611, is undergoing a Phase I/II trial in severe sepsis - a major cause of mortality in the developed world. Finally, AlloCSC-01, targeting acute ischemic heart disease, has demonstrated positive results in a Phase I/II trial in acute myocardial infarction (AMI).
Source:
Cofisem
-
Last Update:
22 Jun 2018
Key Executives
| Chief Executive Officer | Sebastian Wehle | ||||
| Chief Financial Officer | Claudia D'Augusta | ||||
| Investor Relations | Claudia jiménez | ||||
| Human Resources Director | Susana Rojo | ||||
| Source: Cofisem - Last Update: 15 Jun 2018 | |||||
Key figures
| Millenium | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|
| Net sales | 26.790 | 2.240 | 6.286 | 4.301 | |
| Income from ordinary activities | 26.790 | 2.240 | 6.286 | 4.301 | |
| Operating income | -53.180 | -3.027 | -24.076 | -12.563 | -16.013 |
| Cost of net financial indebtedness | -6.849 | -7.132 | -6.377 | -867 | -34 |
| Equity-Accounted companies' contribution to results | |||||
| Net profit from discontinued activities | -1.605 | -2.048 | |||
| Net income | -74.826 | 3.802 | -35.069 | -12.990 | -18.390 |
| Net income (group share) | -74.826 | 3.802 | -35.069 | -12.990 | -18.390 |
| Fiscal year end | 12,17 | 12,16 | 12,15 | 12,14 | 12,13 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | |||||
| Source: Cofisem - Last Update: 22 Jun 2018 | |||||
Shareholder information
Address
TiGenix NV
box 2 Romeinse straat 12
BE-3001
Heverlee, Leuven, Vlaams-Brabant
Belgium
Phone number:
+32 (0)16 39 60 60
Fax:
+32 (0)16 39 79 70
Source:
Cofisem
-
Last Update:
22 Jun 2018